PreciThera is a biotechnology company focused on developing targeted therapies for cancer treatment using proprietary drug delivery systems that enhance the efficacy of existing medications. The company addresses the challenge of drug resistance in tumors by improving the precision and effectiveness of therapeutic agents, ultimately aiming to increase patient survival rates.
Funding
$36M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing cancer treatments often face challenges related to drug resistance, limiting their effectiveness and impacting patient survival rates. Traditional drug delivery systems may not precisely target tumor cells, leading to systemic toxicity and reduced therapeutic efficacy.
Solution
PreciThera is a biotechnology company developing targeted cancer therapies using advanced drug delivery systems to enhance the efficacy of existing medications. Their approach aims to overcome drug resistance by improving the precision with which therapeutic agents reach tumor cells, thereby increasing their effectiveness. By focusing on targeted delivery, PreciThera seeks to minimize off-target effects and improve patient outcomes in cancer treatment. The company leverages proprietary technologies to create drug delivery systems that can selectively target cancer cells while sparing healthy tissue. This targeted approach has the potential to improve the therapeutic index of existing drugs and offer new treatment options for patients with resistant tumors.
Target Audience
PreciThera's primary customers are cancer patients, oncologists, and pharmaceutical companies seeking more effective and targeted cancer treatments.
Features
- Proprietary drug delivery systems for targeted cancer therapy
- Enhanced precision in delivering therapeutic agents to tumor cells
- Technologies designed to overcome drug resistance mechanisms